Imatinib use extended

The licence for Glivec (imatinib) has been extended to include the treatment of adult patients with: - newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukaemia integrated with chemotherapy, or as monotherapy in patients with relapsed or refractory disease. - unresectable dermatofibrosarcoma protuberans or patients with recurrent and/or metastatic disease who are not eligible for surgery.

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

More from MIMS

Additional tiotropium inhaler available to prescribe

Additional tiotropium inhaler available to prescribe

Acopair is delivered by the dry powder NeumoHaler device.

Drug shortages - live tracker

Drug shortages - live tracker

Use our constantly updated shortages tracker to check...

New products - live tracker

New products - live tracker

EXCLUSIVE TO SUBSCRIBERS See the latest products added...

New and deleted indications - live tracker

New and deleted indications - live tracker

EXCLUSIVE TO SUBSCRIBERS See the latest changes to...